---
layout: default
title: Cetrorelix
parent: 僅模型預測 (L5)
nav_order: 98
evidence_level: L5
indication_count: 10
---

# Cetrorelix
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cetrorelix: From Undocumented Original Indication to Hypertrichosis

## One-Sentence Summary

> Cetrorelix is a GnRH (gonadotropin-releasing hormone) receptor antagonist that suppresses pituitary LH/FSH secretion; its original approved indication is not documented in the current evidence pack.
> The TxGNN model's top-ranked prediction is **Hypertrichosis (disease)**, with a score of **99.98%**,
> but this candidate is currently supported by **0 clinical trials** and **0 publications**, and the accompanying mechanistic rationale itself flags the prediction as likely graph-topology noise rather than a genuine pharmacological link.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in evidence pack (no `original_indications` on file; drug not currently marketed in Germany) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.98% (rank 545 among all candidates) |
| Evidence Level | L5 |
| Germany Market Status | ✗ Not Marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed DrugBank mechanism-of-action text is currently unavailable (flagged as a **High-severity data gap, DG002**). Based on the mechanistic description accompanying this prediction, cetrorelix is known to act as a **GnRH receptor antagonist**, blocking the pituitary release of LH/FSH — the same axis targeted by GnRH agonists/antagonists used in reproductive endocrinology.

However, the rationale explicitly generated for this candidate states that hypertrichosis is primarily driven by **local hair-follicle growth-cycle regulation**, not by the hypothalamic-pituitary-gonadal (HPG) axis. There is **no established mechanistic pathway** connecting GnRH receptor blockade to hair-follicle biology. The evidence pack's own assessment concludes that the high TxGNN score likely reflects **proximity of disease nodes in the knowledge graph** (e.g., shared association with reproductive/endocrine disease clusters) rather than a real pharmacological relationship.

Notably, when reviewing the full set of 10 TxGNN predictions for this drug, one lower-ranked candidate — **central precocious puberty 1** (rank 10, score 99.29%) — has a substantially stronger mechanistic rationale: it is a GnRH-dependent (central) condition directly addressable by GnRH receptor blockade, mechanistically parallel to the established use of GnRH agonists (e.g., leuprolide) in this condition. This candidate has been separately flagged internally as a "Research Question" (decision stage S1) rather than "Hold," despite having no clinical trial or literature evidence yet. It may warrant independent evaluation outside the scope of this report's primary candidate.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Germany Market Information

Cetrorelix currently holds **0 marketing authorizations** in Germany (market status: not marketed), so no license-level product data is available for this report.

---

## Safety Considerations

Detailed TFDA/label warning and contraindication data has not yet been retrieved and is flagged as a **Blocking-severity data gap (DG001)** — this must be resolved before any Stage 1 (S1) safety pre-assessment can proceed. Drug-drug interaction data was queried but returned no results.

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (hypertrichosis) has no supporting clinical trial or literature evidence (L5) and its own mechanistic rationale flags it as a likely false positive driven by knowledge-graph proximity rather than real pharmacology. Combined with a **Blocking** data gap on TFDA/label safety information, this candidate does not currently meet the bar to advance.

**To proceed, the following is needed:**
- Resolve DG001 (Blocking): retrieve and parse the official label/package insert for warnings and contraindications
- Resolve DG002 (High): obtain DrugBank-confirmed mechanism of action to properly evaluate mechanistic plausibility
- If pursuing repurposing further, redirect evaluation resources toward **central precocious puberty 1** (rank 10), which has a stronger mechanistic basis but currently lacks any clinical or literature evidence — a dedicated literature/trial search for this indication is recommended before further scoring
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

